| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Programmed cell death 1 ligand 2, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2, Butyrophilin B7-DC, B7-DC, CD273, PDCD1LG2, B7DC, CD273, PDCD1L2, PDL2 |
| Entrez GeneID | 80380 |
| WB Predicted band size | 31.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This PDCD1LG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 46-75 amino acids from the N-terminal region of human PDCD1LG2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于PDCD1LG2(PD-L2)N端抗体的参考文献，涵盖其应用与功能研究：
---
1. **文献名称**：*PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer*
**作者**：Yearley JH, et al.
**摘要**：本研究通过N端特异性PDCD1LG2抗体进行免疫组化分析，揭示了PD-L2在多种实体瘤中的表达模式，并探讨其与PD-L1表达的差异性。结果显示，PD-L2在部分肿瘤微环境中的树突状细胞上高表达，可能影响PD-1/PD-L1抑制剂疗效。
---
2. **文献名称**：*Characterization of PD-1/PD-L2 Interaction in T Cell Suppression*
**作者**：Latchman YE, et al.
**摘要**：利用N端靶向的PDCD1LG2抗体，研究者通过Western blot和流式细胞术验证了PD-L2蛋白在激活的巨噬细胞中的表达。实验表明PD-L2与PD-1结合后可抑制T细胞活化，提示其在免疫检查点中的独立调控作用。
---
3. **文献名称**：*Development of a Novel Anti-PD-L2 Antibody for Functional Studies*
**作者**：Chen S, et al.
**摘要**：该文献报道了一种针对PDCD1LG2 N端表位的兔单克隆抗体的开发与验证。通过ELISA和免疫沉淀实验证明其高特异性，并成功应用于小鼠模型中的阻断实验，显示PD-L2阻断可增强抗肿瘤免疫反应。
---
**备注**：上述文献为示例，实际引用时建议通过PubMed或Google Scholar以关键词“PDCD1LG2 antibody N-terminal”检索最新研究，并关注高影响力期刊(如*Nature Immunology*、*Cancer Research*)的相关论文。
The PDCD1LG2 (N-term) antibody is designed to target the N-terminal region of the programmed cell death 1 ligand 2 (PDCD1LG2), also known as PD-L2 or CD273. PD-L2 is a transmembrane protein belonging to the B7 family of immune checkpoint regulators, primarily expressed on antigen-presenting cells (e.g., dendritic cells, macrophages) and certain tumor cells. It binds to the PD-1 receptor on T cells, suppressing T-cell activation and promoting immune tolerance, thereby playing a critical role in modulating immune responses and tumor immune evasion.
Antibodies specific to the N-terminal domain of PD-L2 are valuable tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), flow cytometry, and immunofluorescence to investigate PD-L2's involvement in autoimmune diseases, chronic infections, and cancer. The N-terminal region is often targeted due to its accessibility and conserved epitopes, enabling reliable detection across experimental models.
Commercially available PDCD1LG2 (N-term) antibodies are typically validated for specificity and sensitivity, supporting research into PD-1/PD-L2 pathway dynamics and therapeutic strategies, including checkpoint inhibitor development. Understanding PD-L2's regulatory mechanisms through such antibodies contributes to advancing immunotherapy and biomarker discovery.
×
